Abstract | PURPOSE: METHODS: The clinical interventional case series study included 48 patients (96 eyes) who consecutively and bilaterally received 3 intravitreal bevacizumab injections. The mean age was 76.5±7.5 years (range: 59-88 years). Follow-up was 6 months. Main outcome parameters were best-corrected visual acuity (BCVA) and measurements by optic coherence tomography. The eyes of the same patient were assigned to a study group 1 for the eye with the higher visual acuity at baseline, and study group 2 for the contralateral eye with the lower visual acuity at baseline. RESULTS: The increase in BCVA was significantly (P=0.02) greater in group 2 (0.07±0.25 logarithm of the minimum angle of resolution, LogMAR) than in group 1 (0.05±0.29 LogMAR). The height of a detached retinal pigment epithelium, the height of subretinal fluid, and the tissue thickness of the macula decreased significantly (P<0.05) in group 2 during follow-up, whereas these parameters did not markedly change in the eyes of group 1 (P=0.96, P=0.38, and P=0.07, respectively). The reduction in the height of a detached retinal pigment epithelium and in the height of subretinal fluid was significantly more pronounced in group 2 than in group 1 (P=0.03, P=0.04, respectively). CONCLUSIONS: After an initial set of 3 bilateral bevacizumab injections, patients with bilateral exudative AMD have a higher likelihood for an improvement in vision in the worse-seeing eye at baseline than in the better-seeing eye.
|
Authors | Jost B Jonas, Yong Tao, Florian Rensch |
Journal | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
(J Ocul Pharmacol Ther)
Vol. 27
Issue 4
Pg. 401-5
(Aug 2011)
ISSN: 1557-7732 [Electronic] United States |
PMID | 21810019
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Bevacizumab
|
Topics |
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal, Humanized
(administration & dosage, therapeutic use)
- Bevacizumab
- Exudates and Transudates
- Female
- Follow-Up Studies
- Humans
- Intravitreal Injections
- Macular Degeneration
(drug therapy, physiopathology)
- Male
- Middle Aged
- Retinal Detachment
(drug therapy, etiology)
- Retrospective Studies
- Tomography, Optical Coherence
- Treatment Outcome
- Visual Acuity
(drug effects)
|